154
Views
2
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

, , , , , , & show all
Pages 1964-1968 | Received 07 May 2009, Accepted 23 Aug 2009, Published online: 08 Oct 2009

References

  • van Besien, Ha CS, Murphy S. Risk factors, treatment and outcome of central nervous system recurrence in patients with intermediate grade and immunoblastic lymphoma. Blood 1998;91:1178–1184.
  • Feugier P, Virion JM, Tilly H. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large B cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129–133.
  • Herman TS, Hammond N, Jones S. Involvement of the central nervous system by non-Hodgkin lymphoma: the Southwest Oncology Group experience. Cancer 1979;43:390–397.
  • MacKintosh FR, Colby TV, Podolsky WJ. Central nervous system involvement in non-Hodgkin lymphoma: an analysis of 105 cases. Cancer 1982;49:586–595.
  • Zinzani PL, Magagnoli M, Prologo G. Isolated central nervous system relapse in aggressive non-Hodgkin lymphoma: the Bologna experience. Leuk Lymphoma 1999;32:571–576.
  • Doolittle ND, Abrey LE, Shenkier TN. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collborative Group report. Blood 2008;111:1085–1093.
  • Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantationas compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med 1995;333:1540–1545.
  • Williams CD, Pearce R, Taghipour G. Autologous bone marrow transplantation for patients with non-Hodgkin lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome – a report by the European Bone Marrow Transplant Registry. J Clin Oncol 1994;12:2415–2422.
  • Kasamon YL, Jones RJ, Piantadosi S. High dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transpl 2005;11:93–100.
  • Williams CD, Pearce R, Taghipour G. Autologous bone marrow transplantation for patients with non-Hodgkin lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome – a report by the European Bone Marrow Transplant Registry. J Clin Oncol 1994;12:2415–2422.
  • Alvarnas JC, Negrin RS, Horning SJ. High dose therapy with haematopoietic cell transplantation for patients with central nervous system involvement by non- Hodgkin lymphoma. Biol Blood Marrow Transpl 2000;6:352–358.
  • Hans CP, Weisenburger D, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
  • van Besien K, Przepiorka D, Mehra P. Impact of pre-existing CNS involvement on the outcome of bone marrow transplantation in adult haematologic malignancies. J Clin Oncol 1996;14:3036–3042.
  • Nyman H, Adde M, Karjalainen-Lindsberg ML. Prognostic impact of immunohistochemically defined germinal centre phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930–4935.
  • Moskowitz CH, Zelenetz AD, Kewalramani T. Cell of origin, germinal centre versus nongerminal centre, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383–3385.
  • Nyman H, Jantunen E, Juvonen E. Impact of germinal centre and non-germinal centre phenotypes on overall and failure free survival after high dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 2008;42:93–98.
  • Boehme V, Schmitz N, Zeynalova S. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.